Skip to main content
. 2016 Mar 3;7(12):13269–13284. doi: 10.18632/oncotarget.7906

Table 1. Clinico-pathological characteristics of METABRIC cohort based on WRN and Top1 expression.

Variable WRN mRNA Expression P Values Topo I mRNA Expression P Values
Low High Low High
n (%) n (%) n (%) n (%)
Lymph node stage
Negative 139 (42.8) 896 (54.4) 0.001 835 (52.8) 200 (51.3) 0.389
Positive (1-3) 65 (20.0) 249 (15.1) 243 (15.4) 71 (18.2)
Positive (> 3) 121 (37.2) 501 (30.4) 503 (31.8) 119 (30.5)
Grade
G1 17 (5.4) 152 (9.6) 0.002 155 (10.2) 14 (3.8) 2.2×10−10
G2 113 (36.1) 657 (41.7) 656 (43.1) 114 (31.0)
G3 183 (58.5) 767 (48.7) 710 (26.5) 240 (64.9)
Tumour Size (cm)
T 1a+b (1.0) 14 (4.3) 78 (4.8) 0.073 79 (5.0) 13 (3.3) 0.021
T 1c (> 1.0-2.0) 106 (32.9) 660 (40.8) 634 (40.4) 132 (33.9)
T2 (> 2.0-5) 183 (56.8) 818 (50.0) 782 (49.9) 219 (56.3)
T3 (> 5) 19 (5.9) 79 (4.8) 73 (4.7) 25 (6.4)
NPI
≤ 3.4 46 (14.8) 342 (21.9) 0.005 345 (22.9) 47 (12.8) 2.0×10−5
> 3.4 265 (85.2) 1217 (78.1) 1162 (77.1) 320 (87.2)
Her2 over expression
No 264 (81.0) 1468 (88.9) 7.1×10−5 1424 (89.8) 308 (78.8) 3.2×10−9
Yes 62 (19.0) 183 (11.1) 162 (10.2) 83 (21.2)
ER
Negative 60 (18.4) 410 (24.8) 0.013 354 (22.3) 116 (29.7) 0.002
Positive 266 (81.6) 1241 (75.2) 1232 (77.7) 275 (70.3)
PgR
Negative 155 (47.5) 781 (47.3) 0.936 716 (45.1) 220 (56.3) 8.0×10−5
Positive 171 (52.5) 870 (52.7) 870 (54.9) 171 (43.7)
Genefu subtype
ER-/Her2 - 9 (5.5) 141 (17.0) 1.7×10−4 124 (15.5) 26 (13.1) 0.538
ER+/Her2-/high proliferation 81 (49.4) 285 (34.3) 2.6×10−4 279 (76.2) 87 (23.8) 0.053
ER+/Her2-/low proliferation 45 (27.4) 323 (38.9) 0.005 326 (40.9) 42 (21.2) 1.0×10−5
Her-2 positive 29 (17.7) 81 (9.8) 0.003 67 (8.4) 43 (21.7) 4.9×10−7
PAM50 subtype
PAM50.Her2 52 (17.9) 186 (12.6) 0.014 159 (11.3) 79 (21.4) 4.4×10−7
PAM50.Basal 28 (9.7) 302 (20.4) 1.8×10−5 266 (19.0) 64 (17.4) 0.478
PAM50.LumA 98 (33.8) 617 (41.6) 0.013 613 (43.7) 102 (27.6) 2.0×10−6
PAM50.LumB 112 (38.6) 377 (25.4) 4.0×10−6 365 (26.0) 124 (33.6) 0.004
IntClust subgroups
intClust.1 35 (10.7) 102 (6.2) 0.003 95 (6.0) 42 (10.7) 0.001
intClust.2 17 (5.2) 55 (3.3) 0.097 54 (3.4) 18 (4.6) 0.257
intClust.3 28 (8.6) 262 (15.9) 0.001 251 (15.8) 39 (10.0) 0.003
intClust.4 32 (9.8) 311 (18.8) 8.5×10−5 308 (19.4) 35 (9.0) 9.7×10−7
intClust.5 53 (16.3) 136 (8.2) 7.0×10−6 118 (7.4) 71 (18.2) 1.1×10−10
intClust.6 29 (8.9) 57 (3.5) 1.1×10−5 66 (4.2) 20 (5.1) 0.408
intClust.7 42 (12.9) 147 (8.9) 0.026 157 (9.9) 32 (8.2) 0.302
intClust.8 30 (9.2) 270 (16.4) 0.001 251 (15.8) 49 (12.5) 0.104
intClust.9 48 (14.7) 98 (5.9) 2.9×10−8 117 (7.4) 29 (19.9) 0.978
intClust.10 12 (3.7) 213 (12.9) 2.0×10−6 169 (10.7) 56 (14.3) 0.041

HER2: human epidermal growth factor receptor 2; ER: estrogen receptor; PgR: progesterone receptor; Triple negative: ER−/PgR−/HER2−.

HHS Vulnerability Disclosure